Johnson & Johnson

NYSE:JNJ   11:47:27 AM EDT
170.60
+0.01 (+0.01%)
Products

FDA Approves New Kyprolis Combination Regimen With Darzalex Faspro And Dexamethasone

Published: 12/01/2021 18:41 GMT
Johnson & Johnson (JNJ) - FDA Approves New Kyprolis® (carfilzomib) Combination Regimen With Darzalex Faspro® (daratumumab and Hyaluronidase-fihj) and Dexamethasone for Patients With Multiple Myeloma at First Or Subsequent Relapse.